Bristol Myers Squibb™
U.S. Pharmaceuticals
3401 Princeton Pike, Lawrenceville, NJ 08648

April 13th, 2021

BY ELECTRONIC DELIVERY

Vermont Attorney General's Office 109 State Street
Montpelier, VT 05609
AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(c), and within thirty calendar days of the initial notice provided on 03/27/2021, Bristol-Myers Squibb is providing further information on the introduction of a new prescription drug with a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program:

- ABECMA® (idecabtagene vicleucel) is supplied in one or more infusion bag(s) containing a frozen suspension of genetically modified autologous T cells in 5% DMSO concentration. Each (50/250/500 ML) infusion bag of ABECMA® is individually packed in a metal cassette.

  NDC 59572-0515-01

  NDC 59572-0515-02

  NDC 59572-0515-03

We consider multiple factors when setting a list price for a medicine, including:

- The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs

- Market and business considerations, including:
  - Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world
  - Medical- and patient-service costs; this includes funding growing patient assistance programs
  - Inflationary and capital-investment costs associated to manufacture, storage, and supply

ABECMA® was granted breakthrough therapy designation and priority review by the FDA. Bristol-Myers Squibb obtained rights to ABECMA® as part of the Celgene acquisition, which completed on November 20, 2019.

Based on 2020 Q1-Q2 earnings reports, CAR T commercially infused patients have been estimated to be around 140 patients per month (roughly 800 patients in the first 2 QTRs). BMS is unable to provide an estimated number of patients who will be prescribed ABECMA® each month.

As per 18 V.S.A. § 4637(d), Bristol-Myers Squibb is refraining from disclosing other components noted in 18 V.S.A. § 4637(c) because these components are not in the public domain or publicly available.

In the event Vermont S. 92 and the laws it implements, including 18 V.S.A. § 4637, are found invalid, Bristol-Myers Squibb reserves all of its legal rights. In issuing this notice in an attempt to comply with 18 V.S.A. § 4637, Bristol-Myers Squibb does not waive any legal claims or legal rights related to constitutional or other defects arising under Vermont S. 92.

Sincerely,

Amina Khan
Associate Director, State Price Transparency
Amina.khan@bms.com